# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://www.wsj.com/articles/bausch-plan-to-spin-off-eye-care-business-stuck-in-creditor-standoff-00e49ff8
RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (NYSE:BHC) with a Sector Perform and lowers the price ta...
Bausch Health reports Q2 2024 GAAP EPS of $0.03, missing the consensus of $0.28. Revenue hits $2.403 billion, up 11% YoY. Piper...
Piper Sandler analyst David Amsellem downgrades Bausch Health Companies (NYSE:BHC) from Neutral to Underweight and lowers th...
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively imp...
After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. Th...
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say followin...